Leukotriene E4 (LTE4) is a vital component in the family of leukotrienes, which play a crucial role in the body's inflammatory response. Leukotrienes are chemicals your body releases (for example, when you come into contact with something you're allergic to). As a part of the eicosanoid family, LTE4 is primarily known for its involvement in asthma and allergic reactions, making it a significant target for medical research and treatment strategies. How is Leukotriene E4 (LTE4) formed? The synthesis of leukotrienes, including LTE4, occurs through the metabolism of arachidonic acid, which is a type of fatty acid found in the cell membranes. LTE4 specifically is formed from the sequential conversion of leukotriene A4 (LTA4) to leukotriene C4 (LTC4), and then to leukotriene D4 (LTD4), before finally becoming LTE4. → This process highlights the intricate biochemical pathways involved in inflammation and immune response. In the context of asthma and allergies, LTE4 has been identified as a key mediator. It contributes to a range of symptoms such as: → bronchoconstriction, → increased mucus secretion, → and enhanced vascular permeability, which are hallmark features of these conditions. This has led to the development of various pharmaceutical agents aimed at blocking the effects of LTE4 and other leukotrienes, providing relief for individuals suffering from these chronic conditions. Research into LTE4 has also extended into other areas of health, including its role in cardiovascular diseases and certain types of cancer. Studies are exploring how LTE4’s involvement in inflammatory pathways might influence the development and progression of these diseases, offering new perspectives on treatment and prevention strategies. In summary, Leukotriene E4 is a critical molecule in the field of immunology and inflammation. Its role in asthma, allergies, and potentially in other serious health conditions, underscores the importance of ongoing research in this area. Understanding the mechanisms of LTE4 not only contributes to better management of inflammatory diseases but also opens avenues for new therapeutic interventions in a variety of health disorders. Referenced studies/papers: → A study discussing the functionality of Leukotriene E4 as a full agonist for human cysteinyl leukotriene type 1 receptor-dependent gene expression. This research highlights the significant role of Leukotriene E4 in cellular processes related to gene expression and its potential implications in health and disease [L]. Foster HR, Fuerst E, Branchett W, Lee TH, Cousins DJ, Woszczek G. Leukotriene E4 is a full functional agonist for human cysteinyl leukotriene type 1 receptor-dependent gene expression. Sci Rep. 2016 Feb 2;6:20461. doi: 10.1038/srep20461. PMID: 26830450; PMCID: PMC4735867. → An investigation into the role of urinary Leukotriene E4 as a biomarker in chronic rhinosinusitis, aspirin-exacerbated respiratory disease, and asthma. This comprehensive review emphasizes the diagnostic and prognostic value of Leukotriene E4 in these conditions [L]. Choby G, Low CM, Levy JM, Stokken JK, Pinheiro-Neto C, Bartemes K, Marino M, Han JK, Divekar R, O'Brien EK, Lal D. Urine Leukotriene E4: Implications as a Biomarker in Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2022 Feb;166(2):224-232. doi: 10.1177/01945998211011060. Epub 2021 May 11. PMID: 33973823. → A perspective on Leukotriene E4 as a 'forgotten' mediator, detailing its involvement in various physiological and pathological processes, particularly in the context of bronchial asthma and related conditions [L]. Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol. 2009 Sep;124(3):417-21. doi: 10.1016/j.jaci.2009.04.020. Epub 2009 May 30. PMID: 19482346. → Research that associates elevated urine Leukotriene E4 levels with worse objective markers in nasal polyposis patients. This study contributes to the understanding of the role of Leukotriene E4 in nasal polyps and potentially its utility in disease management [L]. Choby G, O'Brien EK, Smith A, Barnes J, Hagan J, Stokken JK, Strumpf A, Mattos JL, Payne SC, Divekar R. Elevated Urine Leukotriene E4 Is Associated With Worse Objective Markers in Nasal Polyposis Patients. Laryngoscope. 2021 May;131(5):961-966. doi: 10.1002/lary.29137. Epub 2020 Oct 1. PMID: 33001452. → A systematic review and meta-analysis focusing on urinary Leukotriene E4 as a biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD). This comprehensive analysis provides insights into the diagnostic and predictive capabilities of Leukotriene E4 in this specific context [L]. Marquette M, Tailor BV, Calder PC, Curtis PJ, Loke Y, Wilson AM. Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis. Curr Allergy Asthma Rep. 2022 Dec;22(12):209-229. doi: 10.1007/s11882-022-01049-8. Epub 2022 Nov 14. PMID: 36374376; PMCID: PMC9732072.

LGI1 Antibody, Cell-based IFA What is the LGI1 Antibody Test? The LGI1 Antibody, Cell-based IFA test is used to detect antibodies against the Leucine-Rich Glioma-Inactivated 1 (LGI1) protein. This test helps identify certain autoimmune neurological conditions, including a rare type of autoimmune encephalitis, which is a brain inflammation caused by the immune system mistakenly attacking healthy brain cells. Why is this Test Important? The presence of LGI1 antibodies in the blood can indicate LGI1 autoimmune encephalitis, a condition that can cause memory loss, confusion, seizures, and abnormal movements. This disorder is often not caused by an infection or cancer, but rather by the body’s immune system attacking its own brain tissue. Early detection is critical. When caught early, many patients respond well to immune-modulating treatments, and symptoms can significantly improve or even fully resolve. Conditions Linked to LGI1 Antibodies Autoimmune limbic encephalitis (affecting memory and behavior) Focal seizures, often involving facial or arm movements Hyponatremia (low sodium levels in the blood), which can worsen confusion or fatigue Unlike some other autoimmune brain conditions, LGI1 antibody-associated encephalitis is less commonly linked to cancer, making it a non-paraneoplastic form of encephalitis. How is the Test Performed? This test uses a cell-based indirect immunofluorescence assay (IFA) to detect LGI1 antibodies in a blood sample. The cell-based IFA method is highly specific and helps reduce the chance of false positives. What Do the Results Mean? Positive LGI1 antibodies suggest that your immune system is targeting the LGI1 protein, which may be causing neurological symptoms. This result supports a diagnosis of autoimmune encephalitis and may prompt treatment with immunotherapy. Negative results mean LGI1 antibodies were not detected, but this does not fully rule out autoimmune brain conditions. Your doctor may order other tests if symptoms continue. What Should I Do Next? If your test is positive, your healthcare provider may recommend: MRI or EEG to look for brain inflammation or abnormal electrical activity Immunotherapy (like steroids or IVIG) Follow-up with a neurologist who specializes in autoimmune or inflammatory brain diseases Summary The LGI1 Antibody, Cell-based IFA test plays a vital role in diagnosing a treatable form of autoimmune encephalitis. If you’re experiencing unexplained memory loss, seizures, or behavioral changes, this test can help uncover an immune-related cause—and guide you to the right treatment path.

CD40 ligand (CD40L), also known as CD154, is a protein that is primarily expressed on the surface of activated T cells and belongs to a member of the tumor necrosis factor superfamily. Lack of CD40L results in an inability to undergo immunoglobulin class switch and only class IgM antibodies can be generated. CD40L exists as a membrane-bound form with a molecular weight of 33 kDa and as a soluble form with a molecular weight of 18 kDa. Soluble CD40L (sCD40L) is stored in platelet granules and thus its presence in the blood is a biomarker of platelet activation. sCD40L expression is known to be upregulated in atheroma-associated cells.